Induction of Tolerance Via the Sublingual Route: Mechanisms and Applications

Overview

Journal Clin Dev Immunol

Specialty Allergy & Immunology

Date 2011 Nov 24

PMID 22110534

Citations 18

Authors

Philippe Moingeon

Laurent Mascarell

Affiliations

Soon will be listed here.

Abstract

The clinical efficacy of sublingual immunotherapy (SLIT) with natural allergen extracts has been established in IgE-dependent respiratory allergies to grass or tree pollens, as well as house dust mites. Sublingual vaccines have an excellent safety record, documented with approximately 2 billion doses administered, as of today, in humans. The oral immune system comprises various antigen-presenting cells, including Langerhans cells, as well as myeloid and plasmacytoid dendritic cells (DCs) with a distinct localisation in the mucosa, along the lamina propria and in subepithelial tissues, respectively. In the absence of danger signals, all these DC subsets are tolerogenic in that they support the differentiation of Th1- and IL10-producing regulatory CD4(+) T cells. Oral tissues contain limited numbers of mast cells and eosinophils, mostly located in submucosal areas, thereby explaining the good safety profile of SLIT. Resident oral Th1, Th2, and Th17 CD4(+) T cells are located along the lamina propria, likely representing a defence mechanism against infectious pathogens. Second-generation sublingual vaccines are being developed, based upon recombinant allergens expressed in a native conformation, possibly formulated with Th1/T reg adjuvants and/or mucoadhesive particulate vector systems specifically designed to target oral dendritic cells.

Citing Articles

Molecular Events in Immune Responses to Sublingual Influenza Vaccine with Hemagglutinin Antigen and Poly(I:C) Adjuvant in Nonhuman Primates, Cynomolgus Macaques.

Yamamoto T, Hirano M, Mitsunaga F, Wasaki K, Kotani A, Tajima K Vaccines (Basel). 2024; 12(6).

PMID: 38932372 PMC: 11209156. DOI: 10.3390/vaccines12060643.

Clinical and experimental treatment of allergic asthma with an emphasis on allergen immunotherapy and its mechanisms.

Fiala S, Fleit H Clin Exp Immunol. 2023; 212(1):14-28.

PMID: 36879430 PMC: 10081111. DOI: 10.1093/cei/uxad031.

Allergen Release Profiles of Fast-Dissolving Freeze-Dried Orodispersible Sublingual Allergy Immunotherapy Tablets.

Yamamoto T, Ohashi-Doi K, Matsuhara H, Verhoog L, Lindholm M, Lawton S Curr Ther Res Clin Exp. 2022; 96:100678.

PMID: 35813554 PMC: 9260442. DOI: 10.1016/j.curtheres.2022.100678.

Update about Oralair® as a treatment for grass pollen allergic rhinitis.

Klimek L, Brehler R, Mosges R, Demoly P, Mullol J, Wang D Hum Vaccin Immunother. 2022; 18(5):2066424.

PMID: 35704772 PMC: 9302518. DOI: 10.1080/21645515.2022.2066424.

Essential role of submandibular lymph node dendritic cells in protective sublingual immunotherapy against murine allergy.

Miyanaga N, Takagi H, Uto T, Fukaya T, Nasu J, Fukui T Commun Biol. 2020; 3(1):742.

PMID: 33288832 PMC: 7721894. DOI: 10.1038/s42003-020-01466-3.

References

Penagos M, Passalacqua G, Compalati E, Baena-Cagnani C, Orozco S, Pedroza A . Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2007; 133(3):599-609. DOI: 10.1378/chest.06-1425. View

Moller C, Dreborg S, Lanner A, Bjorksten B . Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy. 1986; 41(4):271-9. DOI: 10.1111/j.1398-9995.1986.tb02028.x. View

Jutel M, Akdis M, Blaser K, Akdis C . Mechanisms of allergen specific immunotherapy--T-cell tolerance and more. Allergy. 2006; 61(7):796-807. DOI: 10.1111/j.1398-9995.2006.01175.x. View

Durham S, Varney V, Gaga M, Jacobson M, Varga E, Frew A . Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy. 1999; 29(11):1490-6. DOI: 10.1046/j.1365-2222.1999.00678.x. View

Pauli G, Larsen T, Rak S, Horak F, Pastorello E, Valenta R . Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008; 122(5):951-60. DOI: 10.1016/j.jaci.2008.09.017. View

Bousquet J, Lockey R, Malling H . Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998; 102(4 Pt 1):558-62. DOI: 10.1016/s0091-6749(98)70271-4. View

Mascarell L, Lombardi V, Zimmer A, Louise A, Tourdot S, Van Overtvelt L . Mapping of the lingual immune system reveals the presence of both regulatory and effector CD4+ T cells. Clin Exp Allergy. 2009; 39(12):1910-9. DOI: 10.1111/j.1365-2222.2009.03337.x. View

Senti G, Freiburghaus A, Kundig T . Epicutaneous/transcutaneous allergen-specific immunotherapy: rationale and clinical trials. Curr Opin Allergy Clin Immunol. 2010; 10(6):582-6. DOI: 10.1097/ACI.0b013e32833f1419. View

Urbanek R, Burgelin K, Kahle S, Kuhn W, Wahn U . Oral immunotherapy with grass pollen in enterosoluble capsules. A prospective study of the clinical and immunological response. Eur J Pediatr. 1990; 149(8):545-50. DOI: 10.1007/BF01957689. View

10.

Larche M, Akdis C, Valenta R . Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006; 6(10):761-71. DOI: 10.1038/nri1934. View

11.

Van Overtvelt L, Moussu H, Horiot S, Samson S, Lombardi V, Mascarell L . Lactic acid bacteria as adjuvants for sublingual allergy vaccines. Vaccine. 2010; 28(17):2986-92. DOI: 10.1016/j.vaccine.2010.02.009. View

12.

Moingeon P, Lombardi V, Saint-Lu N, Tourdot S, Bodo V, Mascarell L . Adjuvants and vector systems for allergy vaccines. Immunol Allergy Clin North Am. 2011; 31(2):407-19, xii. DOI: 10.1016/j.iac.2011.03.001. View

13.

Canonica G, Passalacqua G . Noninjection routes for immunotherapy. J Allergy Clin Immunol. 2003; 111(3):437-48; quiz 449. DOI: 10.1067/mai.2003.129. View

14.

Wachholz P, Durham S . Induction of 'blocking' IgG antibodies during immunotherapy. Clin Exp Allergy. 2003; 33(9):1171-4. DOI: 10.1046/j.1365-2222.2003.01765.x. View

15.

Valenta R . The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol. 2002; 2(6):446-53. DOI: 10.1038/nri824. View

16.

Frew A . How does sublingual immunotherapy work?. J Allergy Clin Immunol. 2007; 120(3):533-6. DOI: 10.1016/j.jaci.2007.08.003. View

17.

Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L . Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy. 2006; 61(2):151-65. DOI: 10.1111/j.1398-9995.2006.01002.x. View

18.

Moingeon P . Sublingual immunotherapy: from biological extracts to recombinant allergens. Allergy. 2006; 61 Suppl 81:15-9. DOI: 10.1111/j.1398-9995.2006.01157.x. View

19.

Mascarell L, Lombardi V, Louise A, Saint-Lu N, Chabre H, Moussu H . Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells. J Allergy Clin Immunol. 2008; 122(3):603-9.e5. DOI: 10.1016/j.jaci.2008.06.034. View

20.

Pipet A, Botturi K, Pinot D, Vervloet D, Magnan A . Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy. Respir Med. 2009; 103(6):800-12. DOI: 10.1016/j.rmed.2009.01.008. View